Drugs / 4SCAR-CD44v6 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04427449 | Jun 2026 → Dec 2029 expected | — | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR-CD44v6 T cells | “Another goal of the study is to learn more about the function of the 4SCAR-CD44v6 T cells and their persistency in the patients.” NCT04427449 ↗ |
| Modality | Cell therapy | “CD44v6 CAR-T cell therapy” NCT04427449 ↗ |
| Route | Intravenous | “The engineered T cells will be applied to patients through intravenous delivery.” NCT04427449 ↗ |